Similar articles

• Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy.

  Scattoni V, Raber M, Abdollah F, Roscigno M, Dehò F, Angiolilli D, Maccagnano C, Gallina A, Capitanio U, Freschi M, Doglioni C, Rigatti P, Montorsi F. Scattoni V, et al. Eur Urol. 2010 Jan;57(1):1-8. doi: 10.1016/j.eururo.2009.08.011. Epub 2009 Aug 19. Eur Urol. 2010. PMID: 19720449
• The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis.

  Mold JW, Holtgrave DR, Bisonni RS, Marley DS, Wright RA, Spann SJ. Mold JW, et al. J Fam Pract. 1992 May;34(5):561-8. J Fam Pract. 1992. PMID: 1578205
• The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy.

  Issa MM, Zasada W, Ward K, Hall JA, Petros JA, Ritenour CW, Goodman M, Kleinbaum D, Mandel J, Marshall FF. Issa MM, et al. Cancer Detect Prev. 2006;30(3):269-75. doi: 10.1016/j.cdp.2006.04.007. Epub 2006 Jul 17. Cancer Detect Prev. 2006. PMID: 16844319
• Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3).

  Kirby RS, Fitzpatrick JM, Irani J. Kirby RS, et al. BJU Int. 2009 Feb;103(4):441-5. doi: 10.1111/j.1464-410X.2008.08280.x. Epub 2009 Jan 9. BJU Int. 2009. PMID: 19154510 Review.
• Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.

  Presti JC Jr, Hovey R, Carroll PR, Shinohara K. Presti JC Jr, et al. J Urol. 1996 Nov;156(5):1685-90. J Urol. 1996. PMID: 8863571 Review.